Myriad Genetics stock plunges after UnitedHealth Group announces they will no longer cover genetic tests for mental health ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1 ...

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

UnitedHealth (UNH) on Friday disclosed that it would stop covering multi-panel pharmacogenetic tests, including Myriad’s (MYGN) ...

Myriad Genetics (MYGN) was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to ...

Piper Sandler thinks Myriad Genetics (MYGN), which has seen its shares fall nearly 22% on Friday morning, is trading down on a coverage decision on GeneSight by UnitedHealth (UNH), which will take ...

UnitedHealth (UNH) on Friday disclosed that it would stop covering multi-panel pharmacogenetic tests, including Myriad’s (MYGN) GeneSight, effective January 1, 2025, in a number of plans ...

Election season is in full swing, but as anyone can tell you, campaigns begin to enter their full speed much earlier in the ...

Stephens analyst Mason Carrico notes that Myriad Genetics (MYGN) shares are down about 20% this morning, which the firm ...

Despite discontinuing part of its GeneSight study, Wells Fargo listed Myriad Genetics among its high-conviction ideas for sustained growth into 2025. The company's strategic initiatives and recent ...